HRS-2129

Small molecule

Phase 1Undisclosed / early pipeline
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Acute Pain

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Other / comorbidity
NCT07185594 · Shandong Suncadia Medicine Co., Ltd.
2025-10-24 – 2026-01-30 · Postoperative Analgesia
What this study did
Phase 2 (1)
Other / comorbidity
NCT07706777 · Shandong Suncadia Medicine Co., Ltd.
2026-08-19 – 2026-11 · Acute Gouty Arthritis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06780267 · Shandong Suncadia Medicine Co., Ltd.
2025-03-11 – 2026-04-03 · Postoperative Pain in Orthopaedics
What this study did
Phase 1 (4)
Diabetic Peripheral Neuropathic Pain
Other / comorbidity
NCT07351968 · Shandong Suncadia Medicine Co., Ltd.
2026-03-10 – 2026-07-17 · Moderate Pain in Knee Osteoarthritis, Severe Pain in Knee Osteoarthritis
What this study did
NCT06742840 · Shandong Suncadia Medicine Co., Ltd.
2024-12-30 – 2025-07-02 · Pain
What this study did
NCT06619392 · Shandong Suncadia Medicine Co., Ltd.
2024-10-17 – 2025-01-20 · Pain
What this study did

Competitive landscape

This drug's own stage for Acute Pain: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-2129: this drugStage not on recordSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Bupivacaine Liposome (Exparel)ApprovedSmall moleculeAmide Local Anestheticnot yet gradedNo reviewed efficacy summary in this indication
Suzetrigine (Journavx)ApprovedSmall moleculeVoltage-gated sodium channel NaV1.8Reliable signal
NCT05553366: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5)
NCT05558410: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3)

Upcoming events

No upcoming readouts on record for this asset.